Does hypointense HCC in the Hepatobiliary Phase at Gadoxetate-Enhanced MRI Predict Recurrence After Surgery? A Systematic Review and Meta-analysis.
| Autor: | Braga FA; Department of Radiology, Federal University of São Paulo, São Paulo, Brazil., Torres US; Department of Radiology, Federal University of São Paulo, São Paulo, Brazil; Department of Radiology, Grupo Fleury, São Paulo, Brazil. Electronic address: ulysses.torres@grupofleury.com.br., Iared W; Department of Radiology, Federal University of São Paulo, São Paulo, Brazil., D Ippolito G; Department of Radiology, Federal University of São Paulo, São Paulo, Brazil; Department of Radiology, Grupo Fleury, São Paulo, Brazil. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Academic radiology [Acad Radiol] 2023 Jul; Vol. 30 (7), pp. 1298-1305. Date of Electronic Publication: 2022 Oct 15. |
| DOI: | 10.1016/j.acra.2022.09.015 |
| Abstrakt: | Rationale and Objectives: The aim of the current study was to investigate whether hypointense hepatocellular carcinoma (HCC) in the hepatobiliary phase (HBP) on gadoxetic acid-enhanced MRI at pretreatment is a potential prognostic marker for tumor recurrence within 3 years after surgery conducted for a curative purpose (resection or liver transplantation). Materials and Methods: Systematic review was performed in the PubMed, Embase, Cochrane Library, and LILACS databases. Original articles focused on evaluating HCC signal intensity (SI) in HBP, as well as recurrence at least 3 years after surgery were included in the study. Odds ratio (OR) was measured based on the inverse variance method and the random-effects model. The Quality in Prognosis Studies (QUIPS) tool was used to assess the quality of the included articles. Results: Five studies with 718 patients, in total, were analyzed. The odds ratio of disease recurrence in patients with hypointense HCC in the HBP, within 3 years after surgery, was 3.12 times higher than that observed in patients with hyperintense HCC in the HBP (OR 3.12; 95% CI 1.27-7.68; p = 0.01). Heterogeneity was classified as intermediate (I 2 = 52%). Articles included in the review overall presented a low risk of bias. Conclusion: Hypointense HCC in the HBP on gadoxetic acid-enhanced MRI at pretreatment has increased the likelihood of tumor recurrence in patients subjected to resection or liver transplantation. HCC SI in the HBP is a potential non-invasive imaging biomarker associated with patient prognosis. (Copyright © 2022 The Association of University Radiologists. Published by Elsevier Inc. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|